Abstract
HIV continues to be a global public health issue, even with the availability of effective HIV prevention technologies, including pre-exposure prophylaxis (PrEP). Despite increasing data showing that tenofovir disoproxil fumarate-based oral PrEP is safe and needs minimal monitoring, the HIV testing requirement restricts increasing the length of PrEP dispensing intervals to more than once every 3 months.1 HIV self-testing (HIVST) is acceptable in diverse settings and uptake is generally high,2 but HIVST use for PrEP support is not yet approved by WHO.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
